Zanamivir in the prevention of influenza among healthy adults: A randomized controlled trial

JAMA

Volumn 282, Issue 1, 1999, Pages 31-35

  Monto, Arnold S ^a   Robinson, D Paul ^b   Herlocher, M Louise ^a   Hinson, James M ^b   Elliott, Michael J ^c   Crisp, Adam ^d  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ZANAMIVIR;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; INFLUENZA; INFLUENZA VIRUS; INHALATIONAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS ISOLATION;

EID: 0033532975     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.1.31     Document Type: Article

References (23)

1. Monto AS, Gunn RA, Bandyk MG, et al. Prevention of Russian influenza by amantadine. JAMA. 1979; 241:1003-1007.
2. Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982; 307:580-584.
3. Sabin AB. Amantadine hydrochloride: analysis of data related to its proposed use for prevention of A2 influenza virus disease in human beings. JAMA. 1967; 200:943-950.
4. Monto AS, Arden NH. Implications of viral resistance to amantadine in control of influenza A. Clin Infect Dis. 1992;15:362-367.
5. Postma JU, Van Tilburg W. Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J Am Geriatr Soc. 1975;23:212-215.
6. Oxford JS, Logan IS, Potter CW. In vivo selection of an influenza A2 strain resistant to amantadine. Nature. 1970;226:82-83.
7. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med. 1989;321:1696-1702.
8. Woods JM, Bethell RC, Coates JAV, et al. 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother. 1993;37:1473-1479.
9. von Itzstein M, Dyason JC, Oliver SW, et al. A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs. J Med Chemother. 1996;39:388-391.
10. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med. 1997;337:874-880.
11. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA. 1996;275:295-299.
12. Centers for Disease Control and Prevention. Update: influenza activity - United States, 1997-98 season. MMWR Morb Mortal Wkly Rep. 1998;47: 196-206.
13. Monto AS. The Tecumseh study of respiratory illness, V: patterns of infection with the parainfluenza-viruses. Am J Epidemiol. 1973;97:338-348.
14. Thomas RG, Conlon M. Sample size determination based on Fisher's exact test for use in 2 X 2 tables with low event rates. Control Clin Trials. 1992;13: 134-147.
15. Gart J. Point and interval estimation of the common odds ratio in the combination of 2 x 2 tables with fixed marginals. Biometrika. 1970;57:471-475.
16. Cox DR. A simple example of a comparison involving quantal data. Biometrika. 1966;53:215-220.
17. Koch GG, Edwards S. Clinical efficacy trials with categorical data. In: Peace KE, ed. Biopharmaceutical Statistics for Drug Development. New York, NY: Marcel Dekker Inc; 1998:403-457.
18. Monto AS, Ohmit SE. The evolving epidemiology of influenza infection and disease. In: Brown LE, Hampson AW, Webster RG, eds. Options for the Controt of Influenza III. Amsterdam, the Netherlands: Elsevier Science Publishers; 1996:45-49.
19. Hart GJ, Bethell RC. 2,3-Didehydro-2,4-dideoxy-4-guanidino-N-acetyl-D-neuraminic acid (4-guanidino-Neu5Ac2en) is a slow-binding inhibitor of sialidase from both influenza A virus and influenza B virus. Biochem Mol Biol Int. 1995;36:695-703.
20. Hayden F, Sperber SJ, Belshe R, Clover RA, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother. 1991;35:1741-1747.
21. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis. 1998;178:1257-1262.
22. Schilling M, Povinelli L, Krause P, et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine. 1998;16:1771-1774.
23. Centers for Disease Control and Prevention. Prevention and control of influenza, II: antiviral agents: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1994;43:1-10,72.